Business Wire

AFWERX, the Innovation Arm of the U.S. Air Force, Awards Phase II STTR Contract to Transcend Air

21.6.2022 14:03:00 EEST | Business Wire | Press release

Share

Transcend Air announced today that it was awarded a Phase II Small Business Technology Transfer research and development contract from AFWERX, a Technology Directorate of the Air Force Research Laboratory. Transcend Air, in partnership with Auburn University, will further develop advanced flight control laws for high-speed flight with its Vy 400 vertical takeoff and landing aircraft (VTOL). “Specifically, the high speed flight is referred to as nap-of-the-earth (NOE) flight, which is a demanding regime where an aircraft stays low and follows the contours of terrain to remain undetected,” commented Peter Schmidt, COO of Transcend Air and Principal Investigator.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005201/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Advanced flight control laws developed in simulation (Photo: Business Wire)

Transcend Air is extending its work with Professor Imon Chakraborty and his Vehicle Systems, Dynamics, and Design Laboratory (VSDDL.com) and newly teaming with Professor Ehsan Taheri and his Aero-Astro Computational and Experimental Lab (ACE Lab). Control software will be demonstrated that enables the Vy 400 aircraft to automatically fly nap-of-the-earth in both simulation and real-world flight with 1/5th scale aircraft. The software reduces pilot workload and enables sustained flight in very close proximity to terrain at speeds two to three times faster than helicopters. This capability facilitates the mission of rescuing downed aircrews in one-quarter to one-eighth of the time it currently takes. With that improvement it is projected that nearly double the number of people can be rescued as before.

AFWERX is an arm of the United States Air Force that supports aircraft technology development for commercial and military purposes. VSDDL and ACE Lab are part of the Department of Aerospace Engineering at Auburn University in Auburn, Alabama.

ABOUT TRANSCEND AIR CORPORATION

Transcend Air has designed a family of high speed tiltwing VTOL aircraft. Its Vy 400 is three times faster than helicopters with half the operating costs. Expectations are that the Vy 400 will dominate the VIP transport helicopter segment. It will also enable a new city-center to city-center Aerial Regional Transport service that is up to five times faster door to door, and lower cost as compared with current air travel options. Since 2009, Transcend Air has built and flown 15 prototype VTOL aircraft, giving their patented Vy a long lineage of real-world experience. The Vy 400 will not require new regulatory regimes or air traffic control systems because it utilizes proven technologies that include the General Electric CT7-8 engine and BRS Aerospace whole-aircraft parachute. The Vy 400 brings with it the promise of civil VTOL flight that is within everyone’s reach.

For additional information see www.Transcend.aero

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Peter Schmidt, peter@transcend.aero
t. 781-883-4818

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 13:45:00 EEST | Press release

NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time building and updating planograms and more time acting on opportunities. With greater automation, retailers can improve productivi

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.10.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity awards to the ten newly hired non-executive employees were granted on October 1, 2026 and consisted of options to purchase an aggregate of 97,100 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 46,200 shares. These options have an exercise price per share equal to $11.95, the closing price of the Company’s American De

Global Health Leaders to Convene at Abu Dhabi Future Health Summit 20262.10.2026 13:24:00 EEST | Press release

Global leaders across healthcare, science, technology, policy, and investment will convene at the Abu Dhabi Future Health Summit from 20 to 22 October 2026 to examine how health systems can better anticipate risk and enable earlier intervention as advances in AI, genomics, diagnostics, and health data create new possibilities for understanding health risks earlier. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001283179/en/ Forum panel and speakers at the Abu Dhabi Future Health Summit As health systems respond to the growing burden of chronic disease and the need to help people live longer in good health, the ability to identify changing health risks and act sooner is becoming increasingly important. Hosted by Future Health – A Global Initiative by Abu Dhabi and the Department of Health – Abu Dhabi, the Future Health Summit will be held under the theme 'To Sense is to Predict', exploring the global shift from reactive m

Venture Global and ConocoPhillips Announce 20-Year LNG Sales and Purchase Agreement1.10.2026 23:30:00 EEST | Press release

Today, Venture Global, Inc. (NYSE: VG) and ConocoPhillips (NYSE: COP) announced a new, long-term Sales and Purchase Agreement (SPA) for liquefied natural gas (LNG). Under the SPA, ConocoPhillips will buy 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. "Venture Global is proud to welcome ConocoPhillips, one of the world's leading energy companies, as a long-term partner," said Venture Global CEO Mike Sabel. "This agreement reflects continued market confidence in our proven ability to deliver reliable, low-cost U.S. LNG quickly and at scale. We look forward to supporting ConocoPhillips' growing global LNG portfolio for decades to come." About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye